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Abstract: Two new oxidovanadium(V) complexes, (HNEt3)[VVO2L] (1) and [(VVOL)2μ-O] (2), have 
been synthesized using a tridentate Schiff base ligand H2L [where H2L = 
4-((E)-(2-hydroxy-5-nitrophenylimino)methyl)benzene-1,3-diol] and VO(acac)2 as starting metal 
precursor. The ligand and corresponding metal complexes are characterized by physicochemical 
(elemental analysis), spectroscopic (FT-IR, UV–Vis, and NMR), and spectrometric (ESI–MS) 
methods. X-ray crystallographic analysis indicates the anion in salt 1 features a distorted 
square-pyramidal geometry for the vanadium(V) center defined by imine-N, two phenoxide-O, 
and two oxido-O atoms. The interaction of the compounds with CT–DNA was studied through 
UV–Vis absorption titration and circular dichroism methods. The results indicated that complexes 
showed enhanced binding affinity towards DNA compared to the ligand molecule. Finally, the in 
vitro cytotoxicity studies of H2L, 1, and 2 were evaluated against colon cancer (HT-29) and mouse 
embryonic fibroblast (NIH-3T3) cell lines by MTT assay. The results demonstrated that the com-
pounds manifested a cytotoxic potential comparable with clinically referred drugs and caused cell 
death by apoptosis. 
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1. Introduction 
In the family of the vanadium complexes, the oxoidovanadium Schiff base com-
plexes are the most rapidly growing class owing to their rich underlying features and 
vital role during the process of interaction with various biomolecules [1]. Although va-
nadium exists in different oxidation states from −III to +V, for the higher oxidation states 
(+IV and +V), vanadium is highly stable and can form oxophilic complexes [2–4]. Oxi-
dovanadium complexes have various roles in biochemical processes, such as nitrogen 
fixation, haloperoxidation, and glycogen metabolism [5,6]. In recent years, the investiga-
tion of the antifungal, antibacterial, and anticancer activities of these complexes has be-
come the main subject of many studies. Recently, there is a growing interest in the in 
vitro and in vivo studies of vanadium complexes towards the treatments of diabetes and 
cancer [7,8]. After the discovery of many oxidovanadium drugs, 
bis(maltolato)oxovanadium(IV), BMOV, as glucose and lipid-lowering insulin mimetics, 
the focus on these types of compounds was stimulated [9]. Additionally, the anticancer 
activity of vanadium complexes has been widely examined on trial carcinogenesis and 
tumor-bearing animals [10,11]. The anticancer activity of several oxidovanadium com-
plexes has recently received attention due to physiochemical changes in the solution 
medium leading to reduced systemic toxicity with beneficial effects [12,13]. There are 
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also reports that vanadium accumulates in cancerous cells and tissues more than in 
normal cells [11,14]. For this reason, vanadium complexes have displayed promising 
cytotoxicity against various human cancer cell lines and these complexes were found to 
show better selectivity and higher cytotoxicity with reduced side effects. Therefore, at-
tempts are being made to develop anticancer drugs using these oxidovanadium(V) 
complexes as suitable alternatives to platinum-based drugs [15]. 
In addition, Schiff bases play an immense role in coordination chemistry due to their 
ability to stabilize metal ions in various oxidation states, and their participation in nu-
merous catalytic applications and biological activities [16–18]. The formation of stable 
metal complexes is due to the nitrogen lone pair of electrons present in the azomethine 
(−N=CH) backbone of the ligand molecule [18,19]. Various types of Schiff base ligands 
have been explored for their fascinating and significant properties, for example, com-
plexing ability towards a wide range of transition metals, and applications in biological 
activity [20,21]. Certain oxidovanadium(V) Schiff base complexes have been reported 
earlier as model compounds, displaying biomolecular interactions with proteins and 
bio-ligands such as DNA [8,22,23]. Additionally, it is demonstrated that with increase in 
substitution and planarity of ligands, DNA interactions are enhanced [24]. Furthermore, 
metal complexes which can effectively interact with DNA under physiological conditions 
are considered to be possible contenders for use as therapeutic agents in medicinal ap-
plications and for genomic research [24,25]. Therefore, attempts are being made to de-
velop anticancer drugs using these oxidovanadium(V) complexes as suitable alternatives 
to platinum-based drugs. Reportedly, polyphenolic/polyhydroxy compounds can pre-
vent oxidative damage as they can scavenge reactive oxygen species such as hydroxyl 
radicals and superoxide anions. The prooxidant properties of polyphenolic compounds 
may contribute to tumor cell apoptosis [26–28]. In consideration of the inherent property 
of phenols and other polyhydroxy compounds particularly for medicinal and pharma-
cological applications [29,30], their corresponding complexes might be crucial for inves-
tigation for anticancer activity. 
In continuation of our previous work on the synthesis, characterization, and bio-
logical studies of vanadium(V/IV) complexes [8,13,31–45], here we report a new mono-
nuclear dioxidovanadium(V) (1) as well as an oxido-bridged dinuclear oxidovanadi-
um(V) (2) complex, each with a tridentate ONO donor Schiff base ligand derived from 
2,4-dihydroxybenzaldehyde and 2-amino-4-nitrophenol. Considering the therapeutic 
potential of the synthesized polyphenolic ligand molecule [27,30,46], corresponding ox-
idovanadium(V) complexes were synthesized to further investigate their pharmacologi-
cal activities such as DNA interaction and anticancer activities. The primary objective of 
this current work was to investigate the significant characteristics of these ligand(H2L) 
and oxidovanadium(V) complexes in terms of their applications as anticancer agents. The 
synthesized ligand and respective complexes were characterized by various spectro-
scopic (FT-IR, UV–Vis, and NMR), spectrometric (ESI–MS) techniques and the purity of 
the compounds were confirmed by CHN analysis. Furthermore, the single-crystal X-ray 
crystal structure of 1 was determined. The binding of the complexes toward CT–DNA 
was studied by UV–Vis absorption titration and circular dichroism. Finally, the cytotoxi-
city of the synthesized compounds was determined against HT-29 cell lines by MTT as-
say and for comparison a normal cell line, mouse embryonic fibroblast (NIH-3T3), was 
used. 
2. Results and Discussion  
2.1. Synthesis 
New mononuclear dioxidovanadium(V) (1) and oxido-bridged dinuclear oxi-
dovanadium(V) (2) complexes were synthesized by the reaction of the metal precursor 
[VIVO(acac)2] with a tridentate ONO donor Schiff base ligand(H2L) derived from con-
densation of 2,4-dihydroxybenzaldehyde and 2-amino-4-nitrophenol under reflux con-
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ditions. Scheme 1 depicts the synthetic methods of preparation of the complexes. The 
compounds were characterized by several spectroscopic (FT-IR, UV–Vis, and NMR) and 
spectrometric (ESI–MS) methods, and their purity was further confirmed by CHN ele-
mental analysis. The structure of 1 was determined by single-crystal X-ray crystallog-
raphy.  
 
Scheme 1. Outline of the pathways for the synthesis of (HNEt3)[VVO2L] (1) and [(VVOL)2μ-O] (2). 
2.2. Spectral Characteristics 
2.2.1. IR Spectroscopy 
Selected spectroscopic data of ligand (H2L) and respective complexes (1 and 2) have 
been compiled in the Experimental Section. The IR spectrum of the free ligand (H2L) ex-
hibits one sharp band in the region 3205 cm–1 due to ν(O–H) stretching vibrations, which 
is absent in the corresponding metal complexes due to deprotonation of phenolic hy-
drogen [40]. Furthermore, the stretching band found in the region 1632–1607 cm–1 clearly 
indicates the presence of ν(C=N) in the ligand as well in the complexes [38]. In addition, 
two additional new stretching bands appeared in the region 888 and 947 cm–1 assigned to 
the two ν(V=O) stretching of cis-ν(V=O) groups in 1 whereas for 2 it is observed in the 
region 891 and 975 cm–1. These stretching vibrations are in agreement with the terminal 
V=O groups present in related oxidovanadium(V) complexes [43]. Additionally, a new 
stretching band observed at 819 cm−1 assigned to the ν(V−O−V) residue of complex 2 
which further indicates the existence of a dinuclear species [45]. The representative IR 
spectra of the ligand (H2L) and its corresponding complex 1 are depicted in Figure S1. 
2.2.2. Electronic Spectra 
The UV-visible spectra of the ligand (H2L) and its complexes (1 and 2) were recorded 
in DMSO with a complex concentration of 1.6 × 10−4 M (Figure 1). The spectrum of the free 
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tive complexes show three strong absorption bands in the region 446–264 nm. The low 
energy absorption bands observed for the complexes in the region 422 and 446 nm could 
be attributed to ligand to metal charge transfer (LMCT) transition whereas the high en-
ergy bands appeared in the UV region (361–264 nm) are likely to be due to ligand center 
transitions [34]. 
 
Figure 1. UV–Vis spectra of H2L, 1, and 2 (1.6 × 10−4 M) in DMSO. 
2.2.3. NMR Spectra 
The 1H and 13C{1H} NMR data of ligand was recorded in DMSO-d6. The spectrum of 
H2L exhibits two compounds connected via intermolecular hydrogen bonding as shown 
in Figure S2 due to which two equivalent sets of protons obtained in the NMR. The 1H 
NMR spectra of H2L show singlet resonances in the downfield region in the range δ = 
10.92–8.95, and 8.21 ppm due to –OH, and –CH (azomethine) protons, respectively [42]. 
The aromatic protons were observed in the expected range between δ = 8.20‒6.27 ppm 
[37]. However, in 1, the spectra suggests a mononuclear vanadium(V) complex and it 
exhibits a singlet for each –OH and –HC=N in the region 10.34 and 9.39, ppm respectively 
[42]. The aromatic protons were observed in the expected range between δ = 8.59‒6.77 
ppm and additionally two sets of resonances that is, a quartet at δ = 3.08 and a triplet at 
1.15 ppm were observed for N–CH2- and –CH3, respectively in the aliphatic region, which 
are attributed to the presence of a triethylammonium counterion [42]. In the case of 2 two 
equivalent sets of protons are observed which are attributed to dimerization of the complex 
through μ2-oxido-bridging. The spectra exhibit singlets in the regions δ = 10.44‒9.39 and 
8.66 ppm for –OH and –HC=N, respectively. The aromatic protons were observed in the 
expected range between δ = 8.66‒6.18 ppm [45]. The representative spectra of 1 (1H, 13C, and 
51V NMR) and 2 (1H, and 51V NMR) are depicted in the ESI section (Figures S3–S7). 
2.2.4. ESI Mass Spectra 
The mass spectral data for 1 and 2 were recorded in acetonitrile solution (Figures S8 
and S9). The ESI mass spectra display characteristic molecular ion peaks at m/z 480.10 and 
694.97 for 1 and 2, respectively. In addition to the molecular ion peak, the complex 1 
shows a peak at m/z 467.19 corresponding to the [M + H+ + 0.5 H2O]+ aggregate.  
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2.3. Single-Crystal X-ray Crystallography of 1 
Crystals of salt 1 were obtained enabling a structure determination by X-ray crys-
tallography. Salt 1 crystallizes in the triclinic space group P1̄ with two independent tri-
ethylammonium cations and two complex anions comprising the crystallographic 
asymmetric unit. The molecular structure of the first independent anion is shown in 
Figure 2a while those of the other constituents of the asymmetric unit are shown in Fig-
ure S10. Selected geometric parameters for the independent anions are listed in Table 1. 
The vanadium atom is penta-coordinated within a NO4 donor set provided by an 
imine-N1, two phenoxide-O1, O2, and two oxido-O3, O4 atoms. The five-coordinate 
geometry is distorted from the ideal square-pyramidal and trigonal-bipyramidal geom-
etries as quantified in the values of τ [47]. For the ideal geometries, τ = 0.0 and 1.0, re-
spectively, whereas in the experimental structures τ computes to 0.26 (anion “a”) and 
0.24 (anion “b”). In this description, the V1 atom lies 0.4691(6) Å above the least-squares 
plane through the O1, O2, O4 and N1 atoms [r.m.s. deviation = 0.1663 Å] in the direction 
of the oxido-O3a atom; the comparable parameters for the V2-anion are 0.4935(6) and 
0.0939 Å, respectively. The bond valency for the vanadium atoms, as calculated in 
PLATON [48], amount to 5.07 and 5.11, respectively, consistent with the assignment of 
vanadium(V) centers. 
 
Figure 2. (a) Molecular structure of the first independent complex anion of salt 1 showing atom 
labelling scheme and displacement ellipsoids at the 70% probability level and (b) overlay diagram 
of the independent complex anions of 1: red image, the molecule shown in (a). The molecule anions 
have been overlapped so the O1, C1, and C2 atoms are coincident. 
Table 1. Selected geometric parameters (Å, °) for the independent anions in salt 1. 
Parameter Anion “a” Anion “b” 
V–O1 1.9152(9) 1.8942(9) 
V–O2 1.9735(9) 1.9191(9) 
V–O3 1.6219(10) 1.6356(10) 
V–O4 1.6463(9) 1.6473(10) 
V–N1 2.1658(11) 2.1968(11) 
C7–N1 1.3033(17) 1.2942(17) 
O1–V–O2 155.41(4) 140.66(4) 
O3–V–O4 109.05(5) 108.51(5) 
N1–V–O4 140.02(5) 155.17(5) 
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The tridentate mode of coordination of the Schiff base dianion leads to the formation 
of six- and five-membered chelate rings. The best description of the six-membered ring is 
based on an envelope with the V1 atom being the flap atom. Here, the V1 atom lies 
0.5624(15) Å out of the plane of the remaining atoms [r.m.s. deviation = 0.0348 Å]; the 
equivalent parameters for the second independent anion are 0.5256(15) and 0.0429 Å, 
respectively. By contrast, the five-membered ring for anion “a” is essentially planar ex-
hibiting a r.m.s. deviation of 0.0239 Å with the maximum deviation of 0.0311(6) Å being 
for the N1a atom. However, an envelope conformation is the best description for the 
five-membered chelate ring of anion “b” whereby the V2 atom lies 0.5978(19) Å out of the 
plane of the remaining four atoms [r.m.s. deviation of 0.0066 Å]. The conformational 
differences between the molecules are highlighted in the overlay diagram of Figure 2b. 
Some significant differences in geometric parameters are apparent, especially, the elon-
gation of the V1–O2(phenoxide) bond length compared with the other comparable 
bonds, and the elongation of the V2–N1(imine) bond as well as differences of up to 15° 
in the O1–V–O2 and N1–V–O4 bond angles. Although these may relate to conforma-
tional disparities, the influence of hydrogen bonding interactions cannot be discounted. 
The presence of hydroxyl-O–H…O(oxido) hydrogen bonds link the two independent 
anions into a two-molecule aggregate as shown in Figure 3; the geometric parameters 
characterizing the identified hydrogen bonding interactions in 1 are listed in Table 2. 
These hydrogen bonding interactions are consistent with the lengthening of the V–O4 
bond lengths compared with the V–O3 bonds. Appended to the two-molecule aggregate 
are the triethylammonium cations which form charge-assisted N–H…O3 hydrogen bonds. 
The N3a-cation also forms a hydrogen bond to the O2 atom indicating the H1n atom is 
bifurcated; this interaction accounts, at least partially, for the lengthening of the V1–O2 
bond (see above). As illustrated in Supplementary Figure S11, the four-molecule aggre-
gates are assembled into a three-dimensional architecture featuring hydroxyphenyl-C–
H…O(phenoxide), nitrophenyl-C–H…O(oxide, hydroxyl), methylene-C–H…O(phenoxide, 
oxide and nitro) and methyl-C–H…O(oxide) interactions, as detailed in Table S1. 
Table 2. Geometric parameters (Å, °) characterizing the identified hydrogen bonding contacts 
between the constituents of the asymmetric unit of salt 1 leading to a four-molecule aggregate. 
A H B H…B A...B A–H…B 
O5a H1o O4b 1.825(12) 2.6548(14) 171.3(18) 
O5b H2o O4a 1.830(15) 2.6640(14) 171.7(17) 
N3a H1n O2a 2.466(13) 3.2244(15) 145.4(13) 
N3a H1n O3a 2.224(12) 2.9473(15) 139.8(14) 
N3b H2n O3b 1.918(12) 2.7904(16) 170.7(14) 
 
Figure 3. The four-molecule aggregate in 1 features hydroxyl-O–H…O(oxido) and charge-assisted 
N–H…O3 hydrogen bonds shown as orange and blue dashed lines, respectively. 
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There are relatively few structural precedents for 1 in the crystallographic literature. 
Arguably the most closely related structure is that of [Et3NH][VO2L] where L is the 
1-(((5-chloro-2-oxidophenyl)imino)methyl)naphthalen-2-olate dianion [11]. Here, a very 
similar square-pyramidal coordination geometry is noted with each chelate ring having 
an envelope conformation as seen for anion “b” in 1. 
2.4. DNA-Binding Studies 
2.4.1. UV–Vis Absorption Studies 
The interactions of metal complexes with DNA provide the binding information of 
metal complexes with the DNA helix [49]. Therefore, the absorption study was per-
formed by maintaining the concentration of the complexes constant (25 μM) with varying 
DNA concentrations from 0 to 100 μM. Upon increasing the CT–DNA concentration, 
hypochromic shifts are observed in both the complexes for the maximal peaks (Figure 4). 
Generally, hypochromism or hyperchromism shifts often are observed in the absorption 
spectrum of a metal complex when the complex interacts with DNA [50]. Hypochromism 
in absorption spectra is generally associated with the binding of complexes to DNA 
through the intercalation mode [51]. To compare the DNA-binding affinity of these 
compounds quantitatively, their intrinsic binding constants were calculated with the aid 
of the following equation: [52] 
[   ]
    −    
=
[   ]
    −   
+  
1
   (   −    )
 (1)
where [DNA] is the concentration of DNA base pairs, Kb is binding constant and εa, εf, and 
εb are the apparent extinction coefficients for the complex i.e., Abs/[complex] in the 
presence of DNA, in absence of DNA and fully bound of DNA, respectively. A plot of 
[DNA]/(εa − εf) vs. [DNA] gave a slope and an intercept equal to 1/(εb − εf) and 1/Kb(εb − εf), 
respectively, while the binding constant Kb was calculated from the ratio of the slope to 
the intercept. The intrinsic binding constants Kb were found to be 2.81 × 104 and 2.35 × 104 
M−1 for 1 and 2, respectively (Table 3). From the binding constant values, it is clear that 
complex 1 interacts more strongly with CT−DNA. However, the free ligand H2L itself 
shows good binding activity (1.59 × 104 M−1) with DNA molecules [53,54]. 
  
Figure 4. Absorption spectroscopic study of complex 1 (a) and 2 (b) (25 μM) with increasing con-
centrations of CT–DNA (0–100 μM). The inset shows the plots of [DNA]/(εa – εf) versus [DNA] for 
the titration of the prepared compounds with CT–DNA.  
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Table 3. DNA-binding parameters for 1, 2, and H2L. 
Complex Binding Constants (Kb) (M−1) 
1 2.81 × 104 
2 2.35 × 104 
H2L 1.59 × 104 
2.4.2. Circular Dichroism Studies 
Circular dichroism (CD) studies were performed to investigate the conformational 
changes in CT–DNA upon interaction with the new compounds. The spectra show two 
significant CD bands in the UV region, a positive band at 275 nm due to base stacking 
whereas a negative band at 245 nm is due to right handed helicity [38,51]. In intercalation 
mode of small molecules, there occurs perturbation in the spectra whereas for groove 
binding and electrostatic interaction there will be minimal or no perturbation [38,51]. 
However, from Figure 5, it is observed that there are significant changes in the CD spec-
tra of CT–DNA which further suggest that the tested compounds bind to CT–DNA in an 
intercalating mode. 
 
Figure 5. Circular dichroism spectra of CT–DNA (150 μM) in the presence and absence H2L, and 
complexes (1 and 2) in 50 mM Tris–HCl buffer (pH 7.4). The path length of the cuvette was 5 mm. 
2.5. Cytotoxicity 
According to GLOBOCAN 2020, disease occurrence and mortality due to colorectal 
cancer has increased to 1.9 million. Moreover, it has been placed as the third most and 
second most incidences in terms of mortality in both male and female, respectively. 
Furthermore, the incidence of colorectal cancer has been reported to be the most in east-
ern Asian countries such as India. Therefore, in this study we have chosen a most ag-
gressive colorectal cancer cell line HT-29 [55]. Hence, the cytotoxicity of the oxidovan-
dium(V) complexes (1 and 2) were measured against HT-29 cancer and NIH-3T3 normal 
cells by MTT assay and were compared to the ligand (H2L) alone. The IC50 values are 
listed in Table 4, and the cell viability percentage diagrams are depicted in Figure 6. 
Specifically, the cytotoxicity of 1 and 2 exhibited IC50 values 8.56 ± 0.62, and 9.09 ± 0.03 
μM, respectively, while that of the ligand alone was determined to be 7.75 ± 0.53 μM 
against HT-29 cancer cell line. These findings suggest that with respect to the ligand, the 
coordination to vanadium did not improve its activity; in fact, H2L is marginally more 
active than both of the complexes. As mentioned earlier, the polyphenol groups in ligand 
molecule (H2L) induce apoptosis in cancer cells which is the primary reason towards the 
enhanced toxicity [28,53]. 
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Furthermore, the cytotoxicity of the tested complexes was studied against the nor-
mal cell line NIH-3T3. The NIH-3T3 cell line is one of the most frequently used cell lines 
as the results provided by these tests can easily be compared with data published in the 
literature [56,57]. The results indicated there was a decrease in the cell viability upon the 
same exposure of the compounds. This result indicates that tested complexes were less 
damaging towards NIH-3T3 as compared to cancer cell lines. Additionally, it was ob-
served that the ligand precursor H2L is more selective against HT-29 cells than both 
complex molecules with selectivity index (SI) = 8.94, whereas SI values for 1 and 2 are 7.92 
and 8.77, respectively. On the other hand, under the same experimental conditions the 
tested compounds exhibited comparable cytotoxicity against HT-29 compared with 
commonly used chemotherapeutic drugs such as cisplatin [58]. Furthermore, the results 
obtained on the present study may be also compared with previously reported oxi-
dovanadium(V) complexes of Schiff base ligands such as [VO(sal-L-tryp)(Me-ATSC)], 
[VO(sal-Ltryp)(N-ethhymethohcarbthio)]∙H2O) and, 
[VO(sal-L-tryp)(acetylethTSC)]∙C2H5OH with IC50 ˃ 47 μM against HT-29 cell lines [59]. 
Additionally, we can also compare our results with recent work where two ox-
ido-bridged vanadium(V) complexes of Schiff base ligands 
[{VVO(R-salval)(H2O)}(μ2-O){VVO(R-salval)}] and [{VVO(R-vanval)(CH3OH)}2(μ2-O)] (val 
= valine, sal = salicylaldehyde, and van = o-vanillin) were investigated for cytotoxic 
studies against human hepatoma cell line with IC50 values > 200μM [7].
 
Figure 6. The effect of 1, 2, and H2L on the cell viability of HT-29 and NIH-3T3 cells after 48 h of 
exposure, taking 10, 50, and 100 μM concentrations of the compounds. The cell viability was cal-
culated by MTT assay. Data were reported as the mean ± SD for n = 4. *** p < 0.0001 was considered 
statistically significant. 
Table 4. IC50 values of H2L and Complexes (1 and 2) taking 10, 50, and 100 μM concentrations. 
Compound IC50 (μM) 
 HT-29 NIH-3T3 
1 8.56 ± 0.62 67.85 ± 5.48 
2 9.09 ± 0.03 79.77 ± 4.00 
H2L 7.75 ± 0.53 69.32 ± 4.42 
2.6. Nuclear DAPI Staining Assay 
To examine the apoptotic potential of test compounds in HT-29 cells, DAPI staining 
assay was conducted. Chromatin condensation, cell shrinkage, and nuclear fragmenta-
tion during the process of apoptosis (type I programmed cell death) is a distinguishing 
marker of nuclear change [51]. For this assay HT-29 cells were treated with 20 μM of H2L, 
1 and 2, respectively and then the cells were incubated for 24 h before DAPI nuclear 
staining. Later, the image of cells was captured under fluorescent microscope fitted with 
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a DAPI filter. The nuclear blebbings and brightly condensed chromatin bodies were 
marked by arrows in Figure 7. 
 
Figure 7. Study of apoptosis by morphological changes in nuclei of HT-29 cells. Arrows show the 
morphological changes in the nuclei of HT-29 cells observed on applying H2L, 1, and 2 in compar-
isons to control. 
3. Materials and Methods 
3.1. Materials 
All the starting materials such as 2-amino-4-nitrophenol, and 
2,4-dihydroxybenzaldehyde were purchased from Sigma Aldrich and used without fur-
ther purification. Reagent grade solvents were dried and distilled prior to use. 
[VO(acac)2] was prepared by the reported method [60]. MTT (3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium), DAPI (4′, 
6-diamidino-2-phenylindoledihydrochloride), and CT–DNA were purchased from Sigma 
Aldrich (St. Louis, MO, USA). HT-29 and NIH-3T3 cell lines were procured from Na-
tional Centre for Cell Science (NCCS), Pune, India. CHN analyses were carried out on a 
Vario ELcube CHNS Elemental analyzer. ESI–MS data of the complexes were recorded 
on a Waters XEVO G2-XS QTOF MS instrument operating in positive ion mode. IR 
spectra were recorded on a Perkin-Elmer Spectrum RXI spectrophotometer. 1H and 13C 
NMR spectra were recorded on a Bruker Ultrashield 400 MHz spectrometer in the pres-
ence of SiMe4 as the internal standard. Electronic spectra were recorded on a Shimadzu 
spectrophotometer (UV-2450). 
3.2. Synthesis of Ligands 
The Schiff base ligand H2L was synthesized by refluxing 
2,4-dihydroxy-benzaldehyde and 2-amino-4-nitrophenol in equimolar ratio in ethanol 
following a standard procedure [13]. The resulting compound was isolated through fil-
tration, washed with ethanol, and dried over fused CaCl2 under desiccator conditions. 
The molecular structure of the compound was confirmed by elemental and spectroscopic 
(FT-IR, UV–Vis, and NMR (1H, 13C{1H}) analysis). 
H2L: Yield: 67%. Anal. calcd. for C13H10N2O5 (274.23): C, 56.94; H, 3.68; N, 10.22. Found: C, 
56.81; H, 3.61; N, 10.18. IR (KBr pellet, cm–1): 3205 ν(O–H); 1632 ν(C=N). UV–Vis (DMSO) 
[λmax, nm (ε, M−1 cm−1)]: 317 (6817), 278 (6812). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 
10.92 (s, 1H, –OH), 10.35 (s, 2H, –OH), 9.25 (s, 1H, –OH), 8.95 (s, 2H, –OH), 8.21 (s, 2H, 
HC=N–), 8.20–6.27 (m, 12H, aromatic). 13C{1H} NMR (100 MHz, DMSO-d6): δ (ppm) = 
191.51, 167.47, 165.67, 165.39, 163.71, 162.04, 156.52, 153.69, 140.32, 140.19, 137.87, 133.30, 
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131.57, 130.21, 124.65, 118.13, 116.72, 115.64, 115.53, 114.73, 112.83, 110.52, 110.16, 109.11, 
103.01, 102.67. 
3.3. Synthesis of Oxidovanadium(V) Complexes  
(HNEt3)[VVO2L] (1). This was synthesized by refluxing the H2L (0.27 g, 1 mmol) and 
VO(acac)2 (0.265 g, 1 mmol) in hot absolute ethanol (20 mL) using triethylamine as a base 
for 4 h. Dark brown crystals were obtained from the filtrate after 2–4 days. The crystals 
were filtered and washed with ethanol for X-ray structure determination. 
(HNEt3)[VVO2L] (1): Yield: 0.32 g (70%). Anal. calcd. for C19H24N3O7V (457.35): C, 49.90; H, 
5.29; N, 9.19; found C, 49.87; H, 5.22; N, 9.12. IR (KBr pellet, cm−1): 2986 ν(O–H), 1607 
ν(C=N), 947, 890 ν(V=O). UV–Vis (DMSO) [λmax, nm (ε, M−1 cm−1)]: 428 (6242), 317 (4331), 
265 (4356). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 10.34 (s, 1H,–OH), 9.39 (s, 1H, 
HC=N–), 8.59–6.17 (m, 6H, aromatic), 3.09 (m, 6H, N-CH2), 1.17 (m, 9H, –CH3). 13C{1H} 
NMR (100 MHz, DMSO-d6): δ (ppm) = 169.41, 165.60, 159.26, 136.92, 136.81, 136.33, 
133.50, 125.03, 124.63, 116.14, 115.22, 114.86, 111.05, 46.26, 9.31. 51V NMR (DMSO-d6): δ 
(ppm) = –527.86. ESI–MS: m/z 480.1007 [M + Na]+. 
[(VVOL)2μ-O] (2). This complex was synthesized by refluxing the H2L (0.27 g, 1 mmol) 
and VO(acac)2 (0.265 g, 1 mmol) in hot MeCN (20 mL) for 4 h. Dark brown crystalline 
materials were obtained from the filtrate after 2–4 days. The crystalline materials were 
filtered and washed with ethanol. [(VVOL)2μ-O] (2): Yield: 0.45 g (66%). Anal. calcd. for 
C26H16N4O13V2 (694.30): C, 44.98; H, 2.32; N, 8.07; found C, 44.92; H, 2.22; N, 8.13. IR (KBr 
pellet, cm−1): 2986 ν(O–H), 1607 ν(C=N), 975, 891 ν(V=O). UV–Vis (DMSO) [λmax, nm (ε, 
M−1 cm−1)]: 446 (6037), 361 (1956), 264 (2450). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 
10.44 (s, 1H, –OH), 8.63 (s, 2H, –OH), 8.01–6.18 (m, 12H, aromatic). 13C{1H} NMR (100 
MHz, DMSO-d6): δ (ppm) = 168.18, 163.71, 159.21, 156.82, 143.28, 141.33, 131.72, 121.78, 
118.32, 117.56, 111.07, 108.71, 102.88. 51V NMR (DMSO-d6): δ (ppm) = −575.27, −530.96. 
ESI–MS: m/z 694.9722 [M + H]+. 
3.4. Single-Crystal X-ray Crystallography 
X-ray Intensity data for a brown crystal of 1 (0.06 × 0.19 × 0.24 mm) were measured at 
100 K on Rigaku/Oxford Diffraction XtaLAB Synergy diffractometer (Dualflex, AtlasS2) 
fitted with CuKα radiation (α = 1.54178 Å) so that θmax = 67.1° (= 100% completeness). 
Data reduction, including Gaussian absorption correction, was accomplished with 
CrysAlisPro [61]. The structure was solved by direct-methods [62] and refined (aniso-
tropic displacement parameters and H atoms in the riding model approximation) on F2 
[63]. The O- and N-bound H atoms were located from Fourier difference maps and re-
fined with distance constraints of O–H = 0.84 ± 01 Å and N–H = 0.88 ± 01 Å, respectively. 
A weighting scheme of the form w = 1/[σ2(Fo2) + (0.043P)2 + 0.792P], where P = (Fo2 + 
2Fc2)/3, was introduced towards the end of the refinement. The molecular structure dia-
grams were generated with ORTEP for Windows [64] with 70% displacement ellipsoids, 
and the packing diagrams were drawn with DIAMOND [65]. Crystal data and refine-
ment details are given in Table 5. 
Table 5. Crystallographic data and refinement details for salt 1. 
Formula [C6H16N][C13H8N2O7V] 
Molecular weight 457.35 
Crystal system triclinic 












Dc/g cm−3 1.534 
μ/mm−1 4.621 
Measured data 46958 
Unique data 7061 
Observed data (I  2.0σ(I)) 6958 
No. parameters 559 
R, obs. data; all data 0.025; 0.026 
Rw, obs. data; all data 0.072; 0.072 
Range of residual electron  
density peaks/eÅ−3 −0.58–0.23 
3.5. DNA-Binding Experiments 
3.5.1. UV–Vis Absorption Studies 
The interaction of the ligand and its respective oxidovanadium(V) complexes (1 and 
2) with CT–DNA was investigated by the absorption titration method with a Shimadzu 
spectrophotometer (UV–2450) [39,40,42,51]. The absorption titration of DNA was con-
ducted by using a fixed concentration of metal complex (25 μM) in 50 mM Tris–HCl 
buffer (pH = 7.4), with gradual increases in concentration of the CT–DNA from 0 to 100 
μM. Each of the above experiments was performed in triplicate at room temperature and 
the incubation time was 5 min after the subsequent addition of CT–DNA for each time to 
equilibrate DNA and the complexes properly. 
3.5.2. Circular Dichroism Studies 
Circular dichroism study was performed in a JASCO J-1500 CD Spectrophotometer 
at 25 °C using a quartz cell with 5 mm path length [51]. CD spectra of CT–DNA (150 μM) 
were collected both in the presence and absence of complexes (25 μM) at a wavelength 
range of 230–350 nm in 50 mM Tris–HCl buffer (pH 7.4) (HiMedia), after averaging three 
accumulations and a scan speed of 200 nm/min. 
3.6. Cytotoxicity Analysis through MTT Assay 
The cytotoxicity of the ligand molecule and its respective vanadium(V) complexes 
was evaluated against colon cancer (HT-29) and mouse embryonic fibroblast (NIH-3T3) 
cells using the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium) assay [42]. 
All cell lines were cultured in DMEM (Dulbecco′s phosphate-buffered saline) medium 
supplemented with 10% FBS (Fetal bovine serum) and maintained at 37 °C in a CO2 in-
cubator (5% CO2) and humidified atmosphere (95% humidity). During the MTT assays, 
cells were seeded in 96-well plates at a density of 6 × 103 cells per well after cell counting 
in a hemocytometer and allowed for 70–80% confluence. Then complexes and the ligand 
were dissolved in DMSO at a concentration of 100 mM and suitably diluted in DMEM 
media to achieve final working concentrations of 10, 50, and 100 μM. After 12 h of initial 
seeding, the HT-29 and NIH-3T3 cells were treated with the above prepared concentra-
tions of each complex and further subjected to incubation for 48 h. MTT was dissolved in 
the DPBS (Dulbecco′s Modified Eagle Medium) solution and was added to the culture 
medium. After additional 3 h incubation at 37 °C, the media were carefully removed and 
200 μL of DMSO was added to each well and the absorbance values were determined by 
spectrophotometry at 595 nm with a microplate reader spectrophotometer (Perkin-Elmer 
2030). The results were expressed as percentages of the control. 
% cell viability = [mean OD of the treated cell/mean OD of the control] × 100 
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IC50 value of the compounds was calculated from the absorbance concentration plot 
following standard procedure [51,66]. 
3.7. Nuclear DAPI Staining Assay 
The morphology of nucleus during the cell death of cells in response to treatment 
with the complexes was investigated using fluorescence microscopy (Olympus IX 71). 
DAPI (4′, 6-diamidino-2-phenylindoledihydrochloride) stain was used for this nuclear 
staining assay and was performed according to a standard procedure previously re-
ported [67]. Accordingly, HT-29 cells were treated with treated (20 μM of compound for 
24 h) and untreated cells were fixed with 4% paraformaldehyde for 15 min. Then the cells 
were stained with DAPI and incubated for 5 min at 37 °C after washing two times with 
DPBS. Finally, again after washing with DPBS, the cells were examined by fluorescence 
microscopy. 
4. Conclusions 
In this work, two new oxidovanadium(V) complexes (HNEt3)[VVO2L] (1), and 
[(VVOL)2μ-O] (2) have been synthesized using a Schiff base ligand (H2L) derived from 
2,4-dihydroxybenzaldehyde and 2-amino-4-nitrophenol. The ligand and complexes were 
characterized by FT-IR, UV–Vis, and NMR (1H, 13C, and 51V) spectroscopy, ESI–MS, and 
the purity was confirmed by CHN analysis. The molecular structure of 1 was determined 
by X-ray crystallography indicating a distorted square-pyramidal geometry for the va-
nadium(V) center defined by imine-N, two phenoxide-O, and two oxido-O atoms. 
DNA-binding experiments were conducted using a UV–Vis absorption titration method 
and circular dichroism studies and the results suggested that the ligand as well as the 
complexes have considerable DNA-binding propensity. From the results, complex 1, 
displayed maximum DNA-binding activity with Kb = 2.81 × 104 M−1. From circular di-
chroism studies it was further confirmed that the synthesized molecules interacted with 
DNA through the intercalation mode. Finally, from the results of cytotoxicity studies it is 
confirmed that all the tested compounds including the ligand molecule induce cell death 
against HT-29 cells mainly through the apoptotic mode. However, the ligand molecule 
with IC50 = 7.75 ± 0.53 μM was found more cytotoxic than its corresponding complexes. In 
addition, the cytotoxicity of ligand and complexes was also studied against NIH-3T3 
normal cells, and it was found to be relatively less damaging towards them. In summary, 
the present group of compounds should stimulate further in vitro and in vivo studies of 
related compounds as part of the quest to develop new drugs for the treatment of cancer. 
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